Objective:To observe effects of Salvianolate combined with Doxofylline in treatment of patients with decompensated chronic pulmonary heart disease(cor pulmonale).Methods:A prospective study was conducted on 78 patients with decompensated chronic pulmonary heart disease admitted to this hospital from January 2021 to May 2023.According to the random number table method,they were divided into control group and observation group,39 cases in each group.The control group was treated with Doxofylline,while the observation group was treated with Salvianolate on the basis of that of the control group.The clinical efficacy,the blood gas indexes levels[arterial partial pressure of carbon dioxide(PaCO2),arterial partial pressure of oxygen(PaO2)],the cardiopulmonary function indexes levels[forced expiratory volume in one second(FEV1),maximum ventilation volume(MVV),left ventricular ejection fraction(LVEF)],the inflammatory factor levels[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP)],and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:There were no significant differences in the total effective rate and the incidence of adverse reactions between the two groups(P>0.05).After the treatment,the levels of PaO2,FEV1,MVV and LVEF in the observation group were higher than those in the control group,the level of PaCO2 was lower than that in the control group,and the differences were statistically significant(P<0.05).The levels of IL-6,TNF-α and hs-CRP in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusions:Salvianolate combined with Doxofylline can improve the levels of cardiopulmonary function indexes,improve the levels of blood gas indexes and reduce the levels of inflammatory factors in the patients with decompensated chronic pulmonary heart disease.Moreover,it is superior to single Doxofylline treatment.
维普
万方数据